Kornimate/medical-research-clean huggingface dataset:
the evaluation of artificial intelligence in lifestyle management of diabetic patients in community

Conditions: Diabetes

Summary: the goal of this clinical trial is to learn about the application and effectiveness evaluation of artificial intelligence (ai) in lifestyle management of diabetic patients in community.

to determine the effectiveness of lifestyle intervention through ai on diabetic patients, whether it can improve blood sugar/ blood pressure/ body weight/ blood lipid control in people with type 1 or type 2 diabetes? then find related risk factors. participants will complete the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the ai scale (ai scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result, while the control group received routine lifestyle guidance. all included patients would fill in the patient's medication information according to the information content of the machine reading card, and follow up whether the medication is adjusted. the patient was included in the diabetes management we-chat group, followed up for 3 months /6 months according to the visit plan. the experimental group filled in the lifestyle assessment scale again, and personalized lifestyle intervention programs were provided according to the survey results, while the control group received routine follow-up and lifestyle guidance. researchers will compare the two groups to see if the control of blood glucose, blood pressure, blood lipids and bmi of the experimental group after 6 months of ai-based lifestyle intervention was better than the control group.

Eligibility criteria:
inclusion criteria: * well informed of the procedures of this trial and informed consent is obtained * 18-80 years old, gender is not limited * diagnosed diabetes (according to who1999 diagnostic criteria) * well compliance exclusion criteria: * pregnant or lactating * poor blood glucose control (hba1c\>11%) * a history of malignant tumor * abnormal liver or renal function \[defined as alanine aminotransferase (alt)\>2.5 times higher than normal range, or egfr\<30 ml/min per 1.73 m2\] * poor blood pressure control \[systolic blood pressure (sbp)\>180mmhg, or diastolic blood pressure (dbp)\>110mmhg * with severe heart disease, cardiac function worse than grade ii, anemia (hb\<9.0g/d1) * blood routine test indicates that the white blood cell count (wbc) \<3\*109/l * body mass index (bmi)\<18.5 or ≥35kg/m2 * drug or alcohol abuse * accompanying mental disorder who can't collaborate * abnormal digestion and absorption function * other endocrine diseases * other chronic diseases needed long-term glucocorticoid treatment * with severe infection, immune dysfunction

Keywords: lifestyle intervention artificial intelligence
effect of peritoneal lavage with clindamycin-gentamicin on laparoscopic sleeve gastrectomy

Conditions: Pain

Summary: a prospective, randomized study will be performed in patients undergoing laparoscopic sleeve gastrectomy (lsg) as bariatric procedure. the patients will be randomized into 2 groups: those patients undergoing an intra-abdominal lavage with normal saline (group 1) and those undergoing an intra-abdominal lavage with a gentamicin-clindamycin solution (group 2). postoperative pain and c reactive protein will be investigated 24 hours after surgery.

a prospective, randomized study will be performedin patients undergoing laparoscopic sleeve gastrectomy (lsg) as bariatric procedure. the patients will be randomized into 2 groups: those patients undergoing an intra-abdominal lavage with normal saline (group 1) and those undergoing an intra-abdominal lavage with a gentamicin-clindamycin solution (group 2). postoperative pain and c reactive protein will be investigated 24 hours after surgery.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>40 kg/m2 * bmi \> 35 kg/m2 with the presence of comorbidities associated to obesity * patients undergoing laparoscopic sleeve gastrectomy (lsg) as bariatric procedure. exclusion criteria: * gastroesophageal reflux * preoperative diagnosis of chronic renal failure * uncontrolled psychiatric disorders * active infections * malignancies * any other concomitant pathology considered as a contraindication for bariatric surgery.
laser treatment for lichen sclerosus

Conditions: Lichen Sclerosus Lesion

Summary: fractional ablative laser treatment for lichen sclerosus lesion


Eligibility criteria:
inclusion criteria: * female aged 18 years or older * biopsy-proven vulvar lichen sclerosus lesion * experiencing one or more of the following symptoms of ls: 1. dryness 2. itching 3. burning 4. bleeding 5. blistering 6. soreness 7. easily bruises 8. easily tears 9. ulcerated lesions 10. painful intercourse * negative urine pregnancy test if subject is of childbearing potential before enrollment * absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and sti * ability to understand and sign informed consent, questionnaires, and all investigation requirements * willing to consent to clinical photographs of the treatment area * willing to consent to ultrasound images of the treatment area * willing and able to logistically follow schedule of treatments and follow-up visits exclusion criteria: * pregnancy, less than 3 months postpartum, or planning to become pregnant during the investigation to protect integrity of the data * is a nursing mother * history of uncontrolled malignant disease * active urogenital infection or chronic infection (i.e., candida, herpes, herpes simplex, bacterial vaginosis, trichomoniasis, or other infection) * immunocompromised (e.g., lymphoma, aids, wiskott-aldrich syndrome) * subjects with genital skin disease, psoriasis due to risk of koeberizing * subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin * known allergy or intolerance to local anesthesia * known history of connective tissue disease * known propensity for keloid formations * known medical condition that may affect wound healing * any reason that the investigator deems prohibits participation in the investigation
afletes-mri: a cardiac and cerebral magnetic resonance imaging study in athletes with atrial fibrillation

Conditions: Atrial Fibrillation; Stroke

Summary: participation in exercise improves cardiovascular health. however, long-term endurance exercise may increase the risk of an irregular heart rhythm called atrial fibrillation (af). in af, blood flow is altered, increasing the risk of clot formation in the heart which may enter the circulation and cause a stroke. the risk of stroke can be reduced with the use of blood thinning medication. athletes with atrial fibrillation, due to their healthy lifestyle, are generally felt to be at low risk of stroke and many would not be offered blood thinning treatment using risk scores used in clinical practice. in a recent survey of almost one thousand athletes, the investigators found that there was an increased risk of stroke in those with atrial fibrillation, even in those without other risk factors for stroke. to further investigate these findings, this study will use mri scanning to look at the hearts and brains of athletes aged between 40-64 years old. the researchers will assess athletes with and without atrial fibrillation, as well as some athletes with atrial fibrillation who have had a stroke previously. the mri scans will measure heart size and function as well as blood flow patterns in the heart. the study will determine whether athletes with atrial fibrillation have evidence of stroke on brain mri and whether these are related to abnormal flow patterns. the results will help us decide whether a larger study should be performed.


Eligibility criteria:
inclusion criteria: * male, atrial fibrillation. * 40-64 years of age at the time of enrolment. * primarily (≥50% of competition) competes in an endurance type sport as defined by european society of cardiology 2020 guidelines. * competitive athlete\* * cha2-ds2-vasc =0/1 (excluding previous stroke). * competitive athlete defined by having trained ≥10 years, 6 hours per week as a self-reported average and having participated in at least one competitive event at regional level or above. exclusion criteria: * history of pre-existing cardiovascular disease * previous myocardial infarction, peripheral arterial disease * left ventricular systolic dysfunction (ef \<45%) * heart muscle disease * complex congenital heart disease. * moderate or severe valvular disease. * uncontrolled hypertension (180/100mmhg) * clotting or bleeding disorders, vasculitis * inherited cerebral disease * known to have an estimated glomerular filtration rate \<30 ml/min/1.73m2.
quality control of ce-certified phonak hearing aids - 2020_06

Conditions: Hearing Loss

Summary: phonak hearing devices pass through different development and study phases. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, resulting from the pre-validation studies, they get optimized. prior to product launch, the phonak hearing systems get reviewed by a final quality control in terms of clinical trials. this is a validation study, investigating improved algorithms, features, functions and wearing comfort. this will be a clinical investigation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

this study will investigate the combination of the features to determine if the audiological performance and quality of the new successor of the marvel family shows an improved benefit over phonak audéo marvel before going into the system validation. therefore this study will be a comparative study. the study will determine if hearing impaired users wearing the successor hearing aids, have better initial acceptance with the new precalculation, better sound quality and speech intelligibility, more clarity and loudness comfort in soft and loud environments compared to phonak marvel ric (receiver in channel) hearing aids. another objective of the study is to compare the listening effort with the two different study devices.

Eligibility criteria:
inclusion criteria: * self-reported confidence to using bluetooth smartphone * hearing loss range: moderate and moderate/ severe * experienced hearing aid user * willingness and interest in testing new features * willingness to wear behind the ear hearing aids * informed consent as documented by signature exclusion criteria: * the audiogram is not in the fitting range of the intended hearing aid * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * participant is not able to describe experiences and hearing impressions * participant has finger movement disorders
long-term follow-up study for patients previously treated with a juno car t-cell product

Conditions: Non Hodgkin Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma

Summary: this study will provide long-term follow-up for patients who have received treatment with a juno car t-cell product in a juno-sponsored clinical trial. in this study, patients will be followed for up to 15 years after their last dose of juno car t cells for evaluation of delayed adverse events, presence of persisting car t-cell vector sequences, presence of replication-competent retrovirus (rcr) or lentivirus (rcl), and survival.


Eligibility criteria:
inclusion criteria: * patients who have received at least one dose of a juno car t-cell product (listed above) in a juno-sponsored clinical trial * patients who have provided informed consent for the long-term follow-up study exclusion criteria: * none. all patients who have previously received treatment with a juno car t-cell product are eligible for this long-term follow-up study.

Keywords: long-term follow-up chimeric antigen receptor (car) t cells jcar017 jcarh125
efficacy and safety of the combination of ten elements for 6 months in patients with diabetic neuropathy : a pilot study

Conditions: Diabetic Neuropathies; Diabetes Mellitus; Dietary Supplement

Summary: to investigate the efficacy of superoxide dismutase (sod, 70 ui), palmitoylethanolamide (pea, 300 mg) alpha lipoic acid (ala, 300 mg), vitamins b6 (1.5 mg), b1 (1.1 mg), b12 (2.5 mcg), e (7.5 mg), nicotinamide (9 mg) and minerals (mg 30 mg, zn 2,5 mg) in one tablet in patients with diabetic neuropathy (dn).

to investigate the efficacy of superoxide dismutase (sod, 70 ui), palmitoylethanolamide (pea, 300 mg) alpha lipoic acid (ala, 300 mg), vitamins b6 (1.5 mg), b1 (1.1 mg), b12 (2.5 mcg), e (7.5 mg), nicotinamide (9 mg) and minerals (mg 30 mg, zn 2,5 mg) in one tablet in patients with diabetic neuropathy (dn). patients - methods: in this pilot study, 61 patients with diabetes mellitus type 2 (dmt2, 31 women), with mean duration of dm 17.5 years and mean age 63 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active group, (n=30), or the placebo (n=31) for 6 months. we used michigan neuropathy screening instrument questionnaire and examination (mnsiq and mnsie), measured vibration perception threshold (vpt) and cardiovascular autonomic reflex tests (carts). nerve function was assessed by dpn check \[sural nerve conduction velocity (sncv) and amplitude (snap)\]. sudomotor function was assessed with sudoscan that measures electrochemical skin conductance in hands and feet (esch and escf). pain (ps) questionnaire was administered, also. all patients received metformin for at least 4 years.

Eligibility criteria:
inclusion criteria: * on metformin therapy for at least 4 years * diabetes mellitus type 2 with diabetic neuropathy * painful neuropathy exclusion criteria: * healthy * without diabetic neuropathy * pregant

Keywords: diabetes mellitus neuropathy pain
comparison of prevention and appropiate obstetric interventions for prolonged second stage labor at term pregnancies during vaginal delivery

Conditions: Obstetric Labor Complications; Vacuum Extraction; Failure, Affecting Fetus or Newborn; Complicated Labour/Delivery Livebirth

Summary: randomized control trial for comparison of prevention and appropiate obstetric interventions for prolonged second stage labor at term pregnancies during vaginal delivery.

this study includes prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42. fetal head level will be at or below the ischial spines in all patients.patients with fully dilated cervix will be included in the study and the bladder will be emptied completely on the labor table. patients diagnosed with fetal distress will not be included in the study.indicated patients will be randomly divided into three groups; one group will be only subjected to a fundal pressure (kristaller maneuver), second group will only be subjected to vacuum extraction and the third group will be subjected to both fundal pressure (kristaller maneuver) and vacuum extraction. maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will be evaluated among three randomized groups.

Eligibility criteria:
inclusion criteria: * term pregnancy weeks between 37-42, singleton, vertex presentations * prolonged second stage of labor * fetal head is minimum at the level of ischial spin * maternal incompatibility during/after second stage of labor * complete cervical dilatation exclusion criteria: * fetal distress * uncomplete cervical dilatation * twin pregnancies or polycyesia * pregnancy weeks lower than 37weeks * other than vertex presentations * fetal anomalies

Keywords: labor stage, second
promoting health in people with fibromyalgia

Conditions: Fibromyalgia

Summary: body worn sensors and the internet can be used to self-monitor daily behavior and promote a healthier lifestyle in women with fibromyalgia.

fibromyalgia is among the most common diffuse pain syndromes, affecting about 1 of every 10 rheumatology patients. people with fibromyalgia experience widespread chronic pain and fatigue that negatively influences their activity participation (causes disability) and overall quality of life. the purpose of this 3-year study is to use a cognitive-behavioral intervention to facilitate adoption of a wellness lifestyle in people with fibromyalgia. specifically, we will test the efficacy of a health promotion computer program (balance center) used in conjunction with a wearable sensor (senseweartm) for developing a wellness lifestyle and improving the quality of life of adults with fibromyalgia. balance center software is a health promotion computer program that helps consumers to: (1) establish goals in the areas of physical activity, nutrition, participation in meaningful, productive activities, sleep, stress-reducing activities, and emotional state; (2) monitor progress toward established goals; and, (3) assess the relationship between these areas in one's daily life. in addition, based on consumer input, it offers suggestions for developing a wellness lifestyle. senseweartm, provides objective data about activity level and stress level for consumers to use in combination with the self-assessment data provided by the balance center. in this randomized controlled clinical trial, the experimental (balance center + senseweartm) intervention is compared to a usual care, control group. seventy-two adults (36 = experimental; 36 = control) with fibromyalgia will be randomized and followed for 6 weeks, exclusive of baseline and posttesting. the hypotheses to be tested are: participants randomized to the experimental condition will demonstrate significantly (a) more physical activity, (b) a healthier, wellness lifestyle, and (c) fewer symptoms of fibromyalgia. in addition, the relationship between the decrease in fibromyalgia-related impairment on daily life and physical activity and a wellness lifestyle will be stronger at posttesting than at baseline in the experimental group, compared to the control group. the anticipated outcome of the intervention is more effective self-management of lifestyle and symptoms so that one can "live well with fibromyalgia."

Eligibility criteria:
inclusion criteria: * be at least 18 years of age * meet the american college of rheumatology criteria for fibromyalgia * diagnosed with fibromyalgia at least 1 year prior to admission to the study * have sufficient vision to operate a computer * be english speaking * have a private telephone line exclusion criteria: * live beyond a 40 mile radius of pittsburgh

Keywords: cognitive therapy
mastopexy with autologous augmentation in women after massive weight loss - a clinical, randomized study

Conditions: Weight Loss

Summary: the purpose of this study is to compare two different techniques of mastopexy with autologous augmentation, the lower pole subglandular advancement mastoplasty (loposam) and rubins mastopexy with autologous augmentation, in massive weight loss patients to see if one technique is superior to the other.

in massive weight loss (mwl) patients the breasts often appear deflated following the prominent volume decrease. the breast is not only deflated, the supportive fibrous tissue is lax and the structural properties have changed. in the typical patient the breast base has sunk along with the inframammary crease and the shape of the breast is wide and flat with a significant ptosis. one way of helping these women is to offer a mastopexy with autologous augmentation. there are several different surgical techniques for treating the ptotic and deflated breast in mwl patients. in this study the investigators compare the investigators own technique, loposam, with rubins mastopexy with autologous augmentation. in rubins mastopexy, an extensive re-arrangement of the skin, fat and breast tissue is done and this is supposed to give good long term results. the procedure is however time consuming and extensive. the loposam technique is less extensive and therefore less time consuming and the investigators hypothesis is therefore that the technique has a lower complication rate. women that is referred for mastopexy after mwl and meet the criteria for post bariatric surgery, set by the danish national board of health, and is found to be a suitable candidate for mastopexy with autologous augmentation is invited to participate in the study. sample size assessment has shown that 22 women (11 in each group) is needed and this number of patients is expected to be recruited in 6-9 months. the study design is a prospective randomized trial. preoperative breast measurements and clinical photographs will be compared with measurements and clinical photographs at 3, 6 and 12 months postoperative the primary outcome is operation time but secondary outcomes include economics, breast measurements, cosmetic result and complication rates. with this trial, the investigators hope to demonstrate whether or not one of the two techniques is superior to the other and therefore should be the preferred technique.

Eligibility criteria:
inclusion criteria: * women that meet the danish national board of health criteria for post bariatric surgery, and is found to be a suitable candidate for autologous augmentation exclusion criteria: * severe dementia, making informed consent impossible * non-danish speaking

Keywords: autologous augmentation mastopexy massive weight loss
effects of dual-transcranial direct current stimulation during physical therapy in sub-acute stroke

Conditions: Stroke

Summary: the aim of the present study is to evaluate the possible effect of using dual-tdcs applied during conventional physical therapy on lower limb function in stroke patients.

recently dual-tdcs applied before the conventional physical therapy show positive effect of lower limb performance. however to explore the time during which dual-tdcs can be combined with physical therapy to maximize motor performance is required. results from the present study with be compared with our previous study that used dual-tdcs applied before physical therapy.

Eligibility criteria:
inclusion criteria: 1. age range 18-75 years. 2. first ever-ischemic lesion in the territory of middle cerebral artery or anterior cerebral artery. ct scan/mri result is thus required. 3. sub acute phase of stroke (less than 6 months) 4. able to sit-to-stand and stand-to-sit independently 5. able to walk without physical assistance at least 6 m 6. free of any neurological antecedent, unstable medical conditions or condition that may increase the risk of stimulation such as epilepsy exclusion criteria: 1. pre-stroke disability 2. pregnant 3. be unable to understand the instruction 4. no clear neurological antecedent history or psychiatric disorder 5. excessive pain in any joint of the paretic limb (numerical pain rating score \> 7) 6. presence of intracranial metal implantation, cochlea implant, or cardiac pacemaker 7. subjects are participating in the other protocol or receiving alternative treatment such as acupuncture